Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results